Skip to content
← Clinical Cases

Cystic Fibrosis — clinical cases

29 questions

Sample cases

  1. Case 1

    A 4-week-old infant has a positive newborn screen for cystic fibrosis (CF). Genetic testing identifies only one disease-causing CFTR variant (F508del). According to the Canadian Clinical Consensus Guideline for CFTR Modulator Therapies (Cystic Fibrosis Canada, 2025), what is the sweat chloride threshold, to be met on two occasions, for diagnosing CF?

    • A.Greater than 60 mmol/L
    • B.Greater than 30 mmol/L
    • C.Greater than 40 mmol/L
    • D.Greater than 100 mmol/L
  2. Case 2

    An 8-year-old boy with CF has the genotype F508del/G542X (G542X is a nonsense, minimal-function variant). He has never received a CFTR modulator. Which CFTR modulator regimen is indicated for his genotype?

    • A.Lumacaftor/ivacaftor combination therapy
    • B.Elexacaftor/tezacaftor/ivacaftor plus ivacaftor
    • C.Ivacaftor monotherapy at the weight-based dose
    • D.Tezacaftor/ivacaftor plus evening ivacaftor
  3. Case 3

    A 7-year-old girl with CF (F508del/F508del) weighs 25 kg and is starting elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). Which regimen is correct?

    • A.Two tablets of ELX 100 mg/TEZ 50 mg/IVA 75 mg in the morning and one ivacaftor 150 mg tablet in the evening
    • B.One tablet of ELX 50 mg/TEZ 25 mg/IVA 37.5 mg in the morning and one ivacaftor 75 mg tablet in the evening
    • C.Two tablets of ELX 50 mg/TEZ 25 mg/IVA 37.5 mg in the morning and one ivacaftor 75 mg tablet in the evening
    • D.One packet of ELX 100 mg/TEZ 50 mg/IVA 75 mg granules in the morning and one ivacaftor 75 mg packet in the evening